ABSTRACT
The effects of RX871024, a compound with an imidazoline structure, on cytoplasmic-free Ca2+ concentration ([Ca2+]i) in mouse pancreatic beta-cells were studied. RX871024 modulates [Ca2+]i by at least two mechanisms. One mechanism involves closure of ATP-regulated K+ channels, resulting in membrane depolarization, opening of voltage-gated L-type Ca2+ channels, and a subsequent increase in [Ca2+]i. Another mechanism, reported here for the first time, deals with RX871024-induced mobilization of Ca2+ from nonmitochondrial thapsigargin-sensitive intracellular stores. Reduced glutathione, inhibitors of cytochrome P-450, and monoaminooxidases A and B blocked this Ca2+ mobilization. It is concluded that the mechanism of RX871024-induced Ca2+ mobilization from intracellular stores involves changes in the oxidation/reduction state of the pancreatic beta-cell and may be controlled by cytochrome P-450.
Subject(s)
Calcium/metabolism , Enzyme Inhibitors/pharmacology , Imidazoles/pharmacology , Indoles/pharmacology , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Thapsigargin/pharmacology , Adenosine Triphosphate/pharmacology , Animals , Calcium Channels/physiology , Calcium-Transporting ATPases/antagonists & inhibitors , Cytochrome P-450 Enzyme Inhibitors , Endoplasmic Reticulum/enzymology , Glutathione/pharmacology , Glyburide/pharmacology , Hypoglycemic Agents/pharmacology , Ion Channel Gating/drug effects , Mice , Mice, Obese , Monoamine Oxidase Inhibitors/pharmacology , Oxidation-Reduction , Potassium Channels/physiologyABSTRACT
A novel imidazoline compound, RX871024, was used to investigate the mechanisms by which imidazoline derivatives promote insulin secretion in rat pancreatic beta-cells and HIT T15 cells. RX871024 stimulated insulin release from rat pancreatic beta-cells and HIT T15 cells in a glucose-dependent way. This effect was not related to alpha2-adrenergic, I1-, and I2-imidazoline receptors. RX871024 promoted insulin release by at least two modes of action. One included an increase in cytoplasmic free Ca2+ concentration ([Ca2+]i), subsequent to blocking of ATP-dependent K+ channels, membrane depolarization, and activation of voltage-dependent Ca2+ channels. The other, a more distal effect of imidazoline, affected the exocytotic machinery and was unrelated to changes in membrane potential and [Ca2+]i. The mechanism of RX871024-induced insulin release was dependent on protein kinases A and C. The sensitizing effect of a low dose of RX871024 on glucose-induced insulin secretion suggests that imidazoline compounds of this kind may constitute the basis for development of a new class of oral hypoglycemic agents.
Subject(s)
Imidazoles/pharmacology , Imidazoles/pharmacokinetics , Indoles/pharmacokinetics , Insulin/metabolism , Islets of Langerhans/physiology , Potassium Channels/physiology , Animals , Brimonidine Tartrate , Calcium/metabolism , Cells, Cultured , Cyclic AMP-Dependent Protein Kinases/metabolism , Cytosol/metabolism , Diazoxide/pharmacology , Exocytosis , Glucose/pharmacology , Idazoxan/pharmacology , Insulin Secretion , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Male , Membrane Potentials/drug effects , Phentolamine/pharmacology , Potassium Channels/drug effects , Potassium Chloride/pharmacology , Protein Kinase C/metabolism , Quinoxalines/pharmacology , Rats , Rats, Wistar , Tumor Cells, CulturedABSTRACT
We have recently isolated and cloned a novel endogenous peptide from pig intestine, NK-lysin (NKL). In the present study we show that NKL (1-100 nM) potently and reversibly stimulates insulin secretion in rat pancreatic islets and in the beta-cell line HIT T15. This effect of NKL was not accompanied by changes in cytoplasmic free calcium concentration. The stimulatory activity of NKL on insulin release was also observed in permeabilized islets under Ca2+-clamped conditions. Preincubation of HIT T15 cells with NKL for 1 h or 24 h did not influence cell viability. Possible mechanisms of insulinotropic activity of NKL are discussed.
Subject(s)
Calcium/metabolism , Insulin/metabolism , Islets of Langerhans/metabolism , Proteolipids/physiology , Pulmonary Surfactants/physiology , Animals , Cell Survival , Cricetinae , Cytosol/metabolism , Dose-Response Relationship, Drug , In Vitro Techniques , Insulin Secretion , Intestinal Mucosa/metabolism , Male , Peptides/isolation & purification , Peptides/physiology , Proteolipids/isolation & purification , Pulmonary Surfactants/isolation & purification , Rats , Rats, Wistar , Swine , Tumor Cells, CulturedABSTRACT
The imidazoline compound RX871024 glucose-dependently potentiates the release of insulin in pancreatic islets and beta-cell lines. This activity of the compound is not related to its action by stimulating alpha 2-adrenoceptors and I1- and I2-imidazoline receptors. There are at least three modes of action of RX871024 in beta-cells: (1) RX871024 blocks the ATP-dependent, Ca(2+)-activated, and delayed rectifier K+ channel activity; (2) RX871024 causes mobilization of Ca2+ from thapsigargin-sensitive intracellular stores, the effect probably controlled by cytochrome P450; and (3) the stimulatory activity of RX871024 on insulin release involves interaction of the compound with the exocytotic machinery, unrelated to the changes in membrane potential and cytoplasmic-free Ca2+ concentration, whereas protein phosphorylation plays an important role in this process. The maximal insulinotropic effect of RX871024 is much higher than that of the sulfonylurea glibenclamide. RX871024 stimulates insulin release and normalizes blood glucose levels in rats in vivo without affecting blood pressure and heart rate.
Subject(s)
Calcium/metabolism , Endoplasmic Reticulum/metabolism , Imidazoles/pharmacology , Indoles/pharmacology , Insulin/metabolism , Islets of Langerhans/physiology , Potassium Channel Blockers , Animals , Blood Glucose/metabolism , Blood Pressure/drug effects , Cells, Cultured , Cytoplasm/metabolism , Endoplasmic Reticulum/drug effects , Exocytosis/drug effects , Heart Rate/drug effects , Insulin Secretion , Insulinoma , Islets of Langerhans/drug effects , Kinetics , Male , Membrane Potentials/drug effects , Models, Biological , Pancreatic Neoplasms , Phosphorylation , Rats , Rats, Inbred SHR , Tumor Cells, CulturedABSTRACT
High concentrations of glucose are considered to be toxic for the pancreatic beta-cell. However, the mechanisms underlying beta-cell dysfunction and resulting cell death are not fully characterized. In the present study we have demonstrated that incubation of pancreatic islets and beta-cells from ob/ob mice and Wistar rats with glucose induced a process of apoptotic beta-cell death, as shown by DNA laddering, TdT-mediated dUTP-biotin nick end-labeling (TUNEL) technique, and by using DNA-staining dye HOECHST 33342. The obtained results show that the percentage of apoptotic cells was dependent on glucose concentration, being minimal at 11 mM glucose. At a concentration of 100 microM, aurintricarboxylic acid, an inhibitor of endonuclease activity, almost completely inhibited apoptosis triggered by 17 mM glucose. We have also shown that long term incubation with 100 microM sulfonylurea, tolbutamide, triggered apoptosis in pancreatic beta-cells. The process of beta-cell death induced by high glucose concentration and tolbutamide were Ca2+-dependent, because introduction to the culture medium of 50 microM D-600 or 200 microM diazoxide, which blocked glucose- and tolbutamide-induced [Ca2+]i increase, inhibited apoptosis. Thus, this study shows for the first time that high glucose concentrations and tolbutamide induce apoptosis in pancreatic beta-cells, and that this process is Ca2+-dependent.
Subject(s)
Apoptosis/drug effects , Calcium/metabolism , Glucose/pharmacology , Hypoglycemic Agents/pharmacology , Islets of Langerhans/drug effects , Tolbutamide/pharmacology , Animals , Islets of Langerhans/cytology , Mice , Mice, Obese , Microscopy, Confocal , Microscopy, Fluorescence , Rats , Rats, WistarABSTRACT
The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 microM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 microM imidazoline. RX871024 (1 microM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.
Subject(s)
Glucagon/metabolism , Imidazoles/pharmacology , Indoles/pharmacology , Insulin/metabolism , Islets of Langerhans/metabolism , Somatostatin/metabolism , Animals , Arginine/pharmacology , Female , In Vitro Techniques , Insulin Secretion , Islets of Langerhans/drug effects , Kinetics , Male , Pancreas , Perfusion , Rats , Rats, Wistar , Time FactorsABSTRACT
The objective of this study was to compare effects of RX-871024, a compound with imidazoline structure, and the sulfonylurea glibenclamide, representatives of two groups of ATP-dependent potassium channel (KATP) blockers, on insulin secretion and cytoplasmic free calcium concentration ([Ca2+]i). Furthermore, we studied the interaction of the compounds on these two parameters. The experiments were performed in the perfused rat pancreas, isolated rat pancreatic islets, and dispersed beta-cells. At maximal effective concentrations of the compounds, RX-871024 had a more pronounced insulinotropic effect than glibenclamide, but the increase in [Ca2+]i was similar. Glibenclamide enhanced the insulinotropic effect of suboptimal concentrations of RX-871024 at 3.3 and 16.7 mM glucose. Notably, glibenclamide and RX-871024 also stimulated insulin secretion under Ca(2+)-clamped conditions, i.e., during plasma membrane depolarization with KCl and glucose or in permeabilized islets. The magnitudes of insulin stimulation under the latter types of conditions were similar for both compounds. It is concluded that RX-871024 and the sulfonylurea glibenclamide promote insulin secretion by two mechanisms, namely closure of KATP channels and a direct stimulation of exocytosis. At a similar increase in [Ca2+]i, the maximal stimulatory effect of RX-871024 on insulin secretion was stronger than that of glibenclamide, implying that RX-871024 also affects insulin secretion by a signal transduction pathway that is not activated by glibenclamide.